Small caps stocks with upside
About this video
Key Points:
Selective, well-backed small caps still seen as attractive in a higher-rate environment
Vinyl Group (ASX:VNL) viewed as undervalued, with a transformative Val Morgan Digital deal pending
EVE Health Group (ASX:EVE) seen as a turnaround story via its Limbo erectile dysfunction product
Comparison drawn with LTR Pharma (ASX:LTP), with convenience of delivery highlighted as a differentiator
John Athanasiou from Red Leaf Securities outlines a cautiously optimistic view on small caps, despite what he describes as a “double whammy” of a software sell-off, geopolitical tensions and rising global interest rates. Athanasiou argues that higher rates typically pressure small caps, yet maintains that selective investors in well-backed names can still, in his view, achieve strong returns.
Athanasiou highlights Vinyl Group (ASX:VNL), formerly Jaxsta, as a key pick. He values the music media and technology company at 19 cents per share on a base case and points to what he calls a “transformative” pending acquisition of Val Morgan Digital. He states this deal could give Vinyl Group around 40% of Australia’s digital market, with scope to buy undervalued cultural assets at attractive prices. He considers the presence of major backers, including Richard White, as a significant support for the growth-by-acquisition strategy.
EVE Health Group (ASX:EVE) is another favoured small cap, despite its weak share price performance. Athanasiou focuses on its shift from Manuka honey towards medical products, highlighting a new erectile dysfunction treatment, Limbo. He notes funds were recently raised to pursue TGA approval and compares EVE with LTR Pharma (ASX:LTP), suggesting EVE’s oral strip delivery may be more convenient than LTR’s nasal product and could underpin a re-rating.